IsoRay (ISR) Announces FDA Clearance Supporting Enhanced Loading and Delivery Methods for the Treatment of Lung, Head and Neck, and Other Tumors
More News related to ISR
- C.K. Cooper Initiates Coverage on IsoRay (ISR) with a Buy
- IsoRay (ISR) Reports Mixed Q2 Results
- IsoRay, Inc. Reports Second Quarter Results
- IsoRay Hires Vice President of Research and Development
- IsoRay Announces It Has Provided Seeds to Canada for Research Initiatives to Expand the Use of Cesium-131 for New Cancer Applications
IsoRay, Inc. (Amex: ISR) announced that it has received clearance from the FDA for its Premarket Notification, [510(k)] for Proxcelan(TM) Cesium-131 Brachytherapy Seeds enabling the company to preload Cesium-131 into flexible braided strands and surgical mesh. This FDA clearance allows IsoRay to market Cesium-131 seeds for use in the treatment of cancers well beyond the current prostate market.
This order clears the product for commercial distribution for treatment of lung and head and neck tumors as well as tumors in other organs. While Cesium-131 seeds themselves have been cleared for this indication since 2003, this current 510(k) allows Cesium-131 to be delivered in a new, convenient and sterile format that can be implanted without additional seed loading by the facility.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
